US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
US5849905A
(en)
*
|
1994-11-23 |
1998-12-15 |
Centre National De La Recherche Scientifique |
Biologically active phosphotriester-type nucleosides and methods for preparing same
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US5985558A
(en)
*
|
1997-04-14 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
|
CA2171550C
(en)
*
|
1993-09-10 |
2008-08-26 |
Raymond F. Schinazi |
Nucleosides with anti-hepatitis b virus activity
|
US20020120130A1
(en)
|
1993-09-10 |
2002-08-29 |
Gilles Gosselin |
2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
|
AU5511196A
(en)
*
|
1995-04-21 |
1996-11-07 |
Centre National De La Recherche Scientifique (Cnrs) |
Acyclovir derivatives as antiviral agents
|
FR2733234B1
(fr)
*
|
1995-04-21 |
1997-07-04 |
Centre Nat Rech Scient |
Derives de l'acyclovir comme agents antiviraux
|
ATE346651T1
(de)
|
1995-06-07 |
2006-12-15 |
Univ Emory |
Nucleoside mit anti-hepatitis b virus wirksamkeit
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US6716625B1
(en)
|
1997-04-16 |
2004-04-06 |
Claude Selitrennikoff |
Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
|
US6528271B1
(en)
|
1997-06-05 |
2003-03-04 |
Duke University |
Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
|
US6887906B1
(en)
|
1997-07-01 |
2005-05-03 |
Isispharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US5877309A
(en)
*
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US5968748A
(en)
*
|
1998-03-26 |
1999-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human HER-2 expression
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6684250B2
(en)
|
2000-04-03 |
2004-01-27 |
Quova, Inc. |
Method and apparatus for estimating a geographic location of a networked entity
|
US7279324B2
(en)
|
2001-01-23 |
2007-10-09 |
Duke University |
Nucleic acid encoding G-protein coupled receptor with modified DRY motif
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ585001A
(en)
|
2001-10-09 |
2011-08-26 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EA200401437A1
(ru)
|
2002-04-26 |
2005-04-28 |
Джилид Сайэнс, Инк. |
Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам
|
CA2498777C
(en)
|
2002-09-13 |
2015-01-13 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
US7229976B2
(en)
|
2002-09-26 |
2007-06-12 |
Isis Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
EP1560839A4
(en)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
CHIMERIC OLIGOMER COMPOUNDS AND THEIR USE IN GENE MODULATION
|
AU2003290598A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
ES2420914T3
(es)
|
2002-11-13 |
2013-08-27 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
JP4753863B2
(ja)
|
2003-02-11 |
2011-08-24 |
アンチセンス セラピューティクス リミテッド |
インスリン様増殖因子i受容体発現の調節
|
US8084432B2
(en)
|
2003-02-13 |
2011-12-27 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of pouchitis
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
JP2006524710A
(ja)
|
2003-04-25 |
2006-11-02 |
ギリアード サイエンシーズ, インコーポレイテッド |
キナーゼインヒビターホスホネート抱合体
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
WO2004096233A2
(en)
*
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates
|
WO2004096285A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-infective phosphonate conjugates
|
DK1628685T3
(da)
|
2003-04-25 |
2011-03-21 |
Gilead Sciences Inc |
Antivirale phosphonatanaloge
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
WO2004096287A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
CN1984921B
(zh)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
存活蛋白表达的调节
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
JP5379347B2
(ja)
|
2003-09-18 |
2013-12-25 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
4’−チオヌクレオシドおよびオリゴマー化合物
|
US7425544B2
(en)
|
2003-09-18 |
2008-09-16 |
Eli Lilly And Company |
Modulation of eIF4E expression
|
SI1678194T1
(sl)
|
2003-10-10 |
2014-02-28 |
Alchemia Oncology Pty Limited |
Modulacija sinteze hialuronana in degradacija pri zdravljenju bolezni
|
WO2005044308A1
(en)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Phosphonate analogs of antimetabolites
|
AU2004290298A1
(en)
|
2003-10-24 |
2005-05-26 |
Gilead Sciences, Inc. |
Methods and compositions for identifying therapeutic compounds
|
WO2005044279A1
(en)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Purine nucleoside phosphonate conjugates
|
KR101350837B1
(ko)
|
2003-12-03 |
2014-01-14 |
코다 테라퓨틱스, 인크. |
코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
|
US20080287471A1
(en)
|
2003-12-22 |
2008-11-20 |
Maria Fardis |
4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity
|
EP2700720A3
(en)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNASE H
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
AU2011218664B2
(en)
*
|
2004-07-27 |
2014-08-21 |
Gilead Sciences, Inc. |
Antiviral compounds
|
HUE043207T2
(hu)
*
|
2004-07-27 |
2019-08-28 |
Gilead Sciences Inc |
HIV-gátló vegyületek foszfonát analógjai
|
AU2005272912A1
(en)
|
2004-08-10 |
2006-02-23 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
PL1809303T3
(pl)
|
2004-09-23 |
2019-11-29 |
Arc Medical Devices Inc |
Kompozycje farmaceutyczne i sposoby dotyczące hamowania zrostów włóknistych lub stanów zapalnych przy użyciu fukanów o niskiej zawartości siarczanów
|
JP2008516991A
(ja)
|
2004-10-20 |
2008-05-22 |
アンチセンス セラピューティクス リミテッド |
インテグリンα4発現のアンチセンス調節
|
KR101840445B1
(ko)
|
2005-02-03 |
2018-05-04 |
코다 테라퓨틱스 (엔지) 리미티드 |
항-코넥신 화합물 및 그의 용도
|
ES2852549T3
(es)
|
2005-02-09 |
2021-09-13 |
Sarepta Therapeutics Inc |
Composición antisentido para tratamiento de la atrofia muscular
|
EP2316941A3
(en)
|
2005-02-25 |
2012-03-14 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to IL-4R alpha
|
US8299041B2
(en)
|
2005-04-08 |
2012-10-30 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to acetyl-CoA carboxylases
|
US20060258610A1
(en)
|
2005-05-12 |
2006-11-16 |
Isis Pharmaceuticals, Inc. |
Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
|
AU2006249925A1
(en)
|
2005-05-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Modulation of LMW-PTPase expression
|
EP1924294A4
(en)
|
2005-05-24 |
2010-11-03 |
Isis Pharmaceuticals Inc |
COMPOSITIONS AND USES FOR MODULATING EXPRESSION OF PTPRU
|
DK1910395T3
(da)
|
2005-06-23 |
2013-02-04 |
Isis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulation af SMN2-splejsning
|
CA2616314A1
(en)
*
|
2005-07-27 |
2007-02-01 |
Gilead Sciences, Inc. |
Antiviral phosphonate conjugates for inhibition of hiv
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
EP2428227B1
(en)
|
2006-01-26 |
2016-06-22 |
Ionis Pharmaceuticals, Inc. |
Compositions and their uses directed to Huntingtin
|
EP2275543A3
(en)
|
2006-04-12 |
2011-03-09 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hepcidin
|
WO2007125173A2
(en)
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
EP2023936A4
(en)
|
2006-05-05 |
2010-11-24 |
Isis Pharmaceuticals Inc |
COMPOSITIONS AND THEIR USES ASSOCIATED WITH THE ALPHA PTPR RECEPTOR
|
EP2505649A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of GCGR
|
WO2007134014A2
(en)
|
2006-05-05 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of gcgr
|
AU2007281082A1
(en)
|
2006-08-04 |
2008-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of JNK proteins
|
ES2620472T5
(es)
|
2006-10-18 |
2020-07-09 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
EP2118118B1
(en)
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
WO2009143390A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of rbp4
|
TW201004632A
(en)
*
|
2008-07-02 |
2010-02-01 |
Idenix Pharmaceuticals Inc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20100093667A1
(en)
|
2008-07-08 |
2010-04-15 |
Gilead Sciences, Inc. |
Salts of hiv inhibitor compounds
|
WO2010005850A1
(en)
|
2008-07-08 |
2010-01-14 |
The J. David Gladstone Institutes |
Methods and compositions for modulating angiogenesis
|
CN103429270B
(zh)
|
2008-08-25 |
2016-11-23 |
埃克斯雷德制药有限公司 |
阻止结缔组织生长因子的反义核苷酸及其用途
|
WO2010039548A2
(en)
|
2008-09-23 |
2010-04-08 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
WO2010120511A2
(en)
|
2009-03-31 |
2010-10-21 |
Altair Therapeutics, Inc. |
Method of treating respiratory disorders
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
EP2552203B1
(en)
|
2010-04-01 |
2017-03-22 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2825059A1
(en)
|
2011-02-02 |
2012-08-09 |
Excaliard Pharmaceuticals, Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
EP2673361B1
(en)
|
2011-02-08 |
2016-04-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
EP2691409B1
(en)
|
2011-03-31 |
2018-02-21 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013022967A1
(en)
|
2011-08-11 |
2013-02-14 |
Isis Pharmaceuticals, Inc. |
Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof
|
EP2755983B1
(en)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
EP2794624B1
(en)
|
2011-12-22 |
2019-05-15 |
Geron Corporation |
Guanine analogs as telomerase substrates and telomere length affectors
|
CN102613190A
(zh)
*
|
2012-03-07 |
2012-08-01 |
海南正业中农高科股份有限公司 |
壳寡糖用于提高坐果率的用途
|
EP2839006B1
(en)
|
2012-04-20 |
2018-01-03 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
JP2015529073A
(ja)
*
|
2012-08-20 |
2015-10-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物可逆性基を有するポリヌクレオチド
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
WO2014092572A1
(en)
|
2012-12-12 |
2014-06-19 |
Universiteit Leiden |
Improved methods for cancer treatment with a genotoxic agent
|
EP3007704B1
(en)
|
2013-06-13 |
2021-01-06 |
Antisense Therapeutics Ltd |
Combination therapy for acromegaly
|
EP3041935A1
(en)
|
2013-09-05 |
2016-07-13 |
Sage Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
US10308940B2
(en)
|
2014-06-10 |
2019-06-04 |
Erasmus University Medical Center Rotterdam |
Antisense oligonucleotides useful in treatment of Pompe disease
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
WO2016196670A1
(en)
|
2015-06-01 |
2016-12-08 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type vii collagen
|
JP6768722B2
(ja)
|
2015-07-02 |
2020-10-14 |
大塚製薬株式会社 |
凍結乾燥医薬組成物
|
BR112018007066A2
(pt)
|
2015-10-09 |
2018-10-23 |
Sarepta Therapeutics Inc |
composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
|
CA3007424A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
US10993995B2
(en)
|
2015-12-07 |
2021-05-04 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
JP7033547B2
(ja)
|
2016-04-18 |
2022-03-10 |
サレプタ セラピューティクス, インコーポレイテッド |
酸性アルファ-グルコシダーゼ遺伝子に関連する疾患を処置するためのアンチセンスオリゴマーおよびそれを用いる方法
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
WO2019006455A1
(en)
|
2017-06-30 |
2019-01-03 |
Solstice Biologics, Ltd. |
AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
|
US10688112B2
(en)
|
2017-07-13 |
2020-06-23 |
Emory University |
Lipid disulfide prodrugs and uses related thereto
|
US10851125B2
(en)
|
2017-08-01 |
2020-12-01 |
Gilead Sciences, Inc. |
Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
|
BR112020002280A2
(pt)
|
2017-08-03 |
2020-07-28 |
Otsuka Pharmaceutical Co., Ltd. |
composto farmacológico e métodos purificação do mesmo
|
WO2019039403A1
(ja)
*
|
2017-08-22 |
2019-02-28 |
国立大学法人名古屋大学 |
修飾ポリヌクレオチド
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
US20220267778A1
(en)
|
2019-07-30 |
2022-08-25 |
Shionogi & Co., Ltd. |
Nucleic acid drug targeting murf1
|